The European Patent Office intends to grant TOMA Biosciences a patent that describes methods for determining personalized cancer drug treatment options based on molecular marker testing.
Foster City, CA (PRWEB) June 21, 2016
TOMA Biosciences, Inc., announced today that it has received a notice that the European Patent Office intends to grant TOMA a patent based on a European patent application titled “Methods for Stratifying and Annotating Cancer Drug Treatment Options.”
The European patent application includes fundamental claims describing methods of determining cancer drug treatment options by sequencing validated and non-validated molecular markers in a subject’s sample. TOMA also owns a related U.S. patent.
“Our intellectual property basically describes a comprehensive model for a personalized medicine business,” said Wolfgang Daum, President and Chief Executive Officer of TOMA Biosciences. “Our methods provide an efficient way to disseminate scientific findings, regarding treatment efficacy and identified molecular markers found in patient tumors, to health care providers.”
Wolfgang Daum continued, “We believe that patients and their physicians are in critical need of meaningful information to help them select the best targeted treatment options, which are sometimes experimental treatments or the off-label use of FDA-approved drugs. Peer-reviewed scientific literature provides examples where the efficacy of a cancer drug can be correlated with the status of a molecular marker. We at TOMA provide the tools to clinical laboratories to make this information easily accessible to physicians and their patients.”
TOMA continues to pursue a broad and robust patent portfolio, which also includes rights to a recently issued U.S. Patent for oligonucleotide selective sequencing (OS-Seq) technology and pending applications for many aspects of the TOMA library preparation assays both in the U.S. and worldwide. This combined patent portfolio provides TOMA with an exceptionally strong intellectual property position.
For more information, attend our webinar, ‘The Rapidly Evolving Cancer Genomics IP Landscape’
TOMA Director of Marketing Operations
TOMA Biosciences provides the most effective sequencing solution to identify clinically meaningful changes in the DNA of cancer tumors. TOMA has commercially launched TOMA OS-Seq™ reagent kits to help laboratories and researchers uncover genomic changes in tumors, including many missed by other methods. With an exclusive license to the oligo selective sequencing (OS-Seq) technology invented at Stanford University, TOMA has developed a fast, simple and efficient way to comprehensively analyze all types of tumor samples – even those with limited volume and poor quality. A team of renowned industry specialists is leading the product development, commercialization and regulatory pathways to bring these products to laboratories, hospital systems and research institutions around the world. TOMA is a commercial stage, private venture-backed company headquartered in Foster City, California.
For the original version on PRWeb visit: http://www.prweb.com/releases/2016/06/prweb13491952.htm